BiotechTube
All Reports
❤️

Cardiovascular

Competitive landscape report · 37 products · 16 companies

Executive Summary

The cardiovascular landscape features 37 products in active development across 16 companies. The space remains highly competitive with significant activity across all clinical stages.

8 products are currently in Phase 3 trials, 10 in Phase 2, and 9 in Phase 1. Leading companies by pipeline count include Eli Lilly, Nuwellis, Celltrion.

2 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
Tirzepatide + Tirzepatide PlaceboIdiopathic Intracranial Hypertension (IIH)
Eli Lilly
Approved
85
2
SGLT2i, beta blocker, ARNI, MRA, MTDHeart Failure
Eli Lilly
Approved
85
3
tadalafil + tadalafilHypertension, Pulmonary
Eli Lilly
Phase 3
77
4
Dulaglutide + PlaceboCardiovascular Disease
Eli Lilly
Phase 3
77
5
raloxifene + placeboCardiovascular Diseases
Eli Lilly
Phase 3
77
6
Orforglipron + PlaceboAtherosclerosis Cardiovascular Disease
Eli Lilly
Phase 3
77
7
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgEssential Hypertension
Celltrion
Phase 3
77
8
macitentan 10 mgChronic Thromboembolic Pulmonary Hypertension (CTEPH)
BML, Inc.
Phase 3
76
9
Stepped pharmacologic careHeart Failure
Nuwellis
Phase 3
69
10
Mavacamten + PlaceboObstructive Hypertrophic Cardiomyopathy
LianBio
Phase 3
69

Top Companies by Pipeline Count

1Eli Lilly10 products2Nuwellis4 products3Celltrion4 products4Trevena3 products5Cereno Scientific3 products6Clearside Biomedical2 products7LianBio2 products8AMO Pharma1 products9AM-Pharma1 products10Alteogen1 products

Phase Distribution

Pre-clinical
5
Phase 1
9
Phase 1/2
3
Phase 2
10
Phase 3
8
Approved
2

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports